APPLICATION
By investing in the research and implementation of new radiotracers such as 18F-fluoroestradiol, physicians can accurately identify estrogen-positive disease on a whole-patient level, greatly impacting patient management. More PET radiotracers are being developed to target other cancer receptors, such as human epidermal growth factor receptor 2 (HER2), found on a subset of breast malignancies. Additionally, some radiotracers may be useful in the targeted treatment of breast cancer. Radiopharmaceutical therapies are a combination of a receptor-targeting molecule and a dose of radiation that can bind to a tumor and act as a smart-bomb to target the cancer cells but not normal tissues—precision medicine.